DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Wegovy (semaglutide) for chronic weight management. State telehealth scope, insurance coverage, and verified providers serving Texas residents.
For weight-loss indication, Texas Medicaid coverage is excludes. No Medicaid expansion; weight-loss generally excluded. T2D PA standard. Wegovy requires the weight-loss PA pathway; review Texas Medicaid criteria carefully.
Most Texas commercial plans cover Wegovy with prior authorization. PA criteria typically require BMI ≥ 30 (or ≥ 27 with comorbidity) for weight-loss-indicated drugs, or T2D diagnosis with metformin trial for diabetes-indicated drugs. Step therapy requirements vary by plan.
White-glove telehealth focused on speed and ease. Strongest pick for patients paying cash who want a fast time-to-prescription path with minimal friction.
Built around medical depth. Best for patients with commercial insurance who want a team that fights insurance battles and treats GLP-1 as part of a comprehensive obesity care plan.
Direct-to-consumer compounded semaglutide subscription. Affordable but trades FDA-approval status for price predictability.
Compounded GLP-1 telehealth with consistent monthly pricing. Best for patients who want compounded options without per-dose price escalation.
If insurance denies, the Texas cash-pay route is NovoCare Direct ($499/mo cash-pay). Available nationally; ships to Texas residents through manufacturer-direct fulfillment.
Editorial summary. Texas licensure and insurance rules change quarterly; confirm with your prescriber and plan before relying on any single source. Affiliate disclosure: we earn commission on outbound clicks to provider partners.